Sabba Stephen L 4

What Happened
Stephen L. Sabba, a Director of Ligand Pharmaceuticals (LGND), received equity awards on June 5, 2026: 836 restricted stock units (RSUs) and an additional 2,938 derivative awards (RSU-type), each granted at $0.00. Total units granted = 3,774. These were board-approved grants (transaction code A) and involve no cash outlay by the insider at grant.

Key Details

• Transaction date: 2026-06-05; Filing date (Form 4): 2026-06-09 (timely filed within required business days).
• Price: $0.00 per share (standard for RSU grants); total cash paid = $0.
• Vesting: Awards fully vest on the earlier of (A) the date of the next annual meeting of stockholders following the grant or (B) the first anniversary of the grant (per footnotes).
• Nature: 836 RSUs (explicit RSUs); 2,938 reported as derivative/RSU-type awards — contingent rights to receive common stock on vesting.
• Shares owned after transaction: Not specified in the Form 4 filing.
• No 10b5-1 plan, tax-withholding sale, or sale/exercise reported in this filing.

Context
This is a standard board equity grant to a director, not a market purchase or sale. RSU awards are common compensation and become actual shares only if/when they vest; they do not by themselves indicate buying or selling sentiment.